Medicina Baseada em Evidências
Conferências médicas científicas podem ser facilmente modificadas para favorecer a inclusão de mulheres: um estudo prospectivo.
17 Ago, 2021 | 11:26hEntrevista com a autora: Victoria Salem on improving female inclusion in conferences
Comentários:
Women participate less at conferences, even with gender-balanced delegates – Imperial College London
Women participate less at conferences, even if gender-balanced – study – The Guardian
Comentários no Twitter
🗣conference organisers take note: female chairs and picking first questions from females are easy modifications for scientific medical conferences to improve female inclusion https://t.co/pt722RB6E8
— Dr Sharleen O’Reilly (@OReillySharleen) August 5, 2021
"If women are not visible at conferences, they cannot act as role models…creating a self-perpetuating cycle."
How scientific medical conferences can be easily modified to improve female inclusion. Read in @TheLancetEndo—https://t.co/3vK5KCdqco #GenerationEquality pic.twitter.com/YPaqnlcCZo
— The Lancet (@TheLancet) July 30, 2021
Excellent study @Soc_Endo – a female session chair and the first question asked by a woman significantly increases active female participation at a scientific conference – read @TheLancetEndo and listen to first author Victoria Salem, highly recommended! @MDSEquality @500womensci https://t.co/PWECJ7TLFU
— Wiebke Arlt 💙 😷 Birmingham, Yes Birmingham (@WiebkeArlt) July 30, 2021
Estudo mostra que os médicos superestimam, de maneira significativa, os benefícios dos tratamentos para os pacientes.
13 Ago, 2021 | 12:08h
Comentário no Twitter
All clinicians & trainees should read this study by @dr_dmorgan et al: in this survey N=542 “Clinicians consistently overestimated the chance that treatments would benefit an individual patient.”
Not by a few %age points, but overestimations of >10-20x!https://t.co/o5SSTnztgi
— Awais Aftab (@awaisaftab) August 10, 2021
Estudo clínico Solidarity da OMS entra em uma nova fase com 3 novas drogas candidatas.
12 Ago, 2021 | 12:18hComentário: WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch
Conteúdos relacionados:
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
Comentário no Twitter (fio – clique para saber mais)
WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab— World Health Organization (WHO) (@WHO) August 11, 2021
Vacinação: Efetividade versus eficácia.
12 Ago, 2021 | 12:17hVaccination: Effectiveness versus Efficacy – by Luis Correa, MD
Um vasto estudo sobre tratamento contra COVID-19, organizado pela OMS, está recomeçando. Estes são os medicamentos em análise.
10 Ago, 2021 | 12:39hA giant trial of COVID-19 treatments is restarting. Here are the drugs it’s betting on – Science
Conteúdo relacionado: WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
Dar e receber: atribuição de tratamento ético em estudos controlados.
10 Ago, 2021 | 12:30hGiving and taking: ethical treatment assignment in controlled trials. – The James Lindt Library
Comentário no Twitter
It was a pleasure and an honour to collaborate with @iainchalmersTTi in writing this piece https://t.co/TP66e4FAOd on ethical issue in treatment assignment in clinical trials. #clinicaltrials
— Stephen John Senn (@stephensenn) August 9, 2021
Adaptação de intervenções para novos contextos – A diretriz ADAPT: “O uso de intervenções baseadas em evidência previa em novos contextos pode ser mais eficaz do que desenvolver novas intervenções.”
9 Ago, 2021 | 11:25hAdapting interventions to new contexts—the ADAPT guidance – The BMJ
Comentário no Twitter
"Although some interventions transfer well, effectiveness and implementation often depend on the context."
This paper presents new evidence and consensus informed guidance for adapting and transferring interventions to new contextshttps://t.co/of1ojFR6VD
— The BMJ (@bmj_latest) August 8, 2021
Estudo falho sobre ivermectina destaca os desafios dos estudos sobre medicamentos para COVID.
6 Ago, 2021 | 11:49hFlawed ivermectin preprint highlights challenges of COVID drug studies – Nature
Conteúdos relacionados:
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?